Holly Lofton at NYU pointed out that skipping brand-name safety frameworks can leave patients exposed to unnecessary risks.
Second, study populations have been heterogeneous with respect to diabetes status, obesity, renal function, baseline cardiovascular disease, and HF phenotype, which may limit generalizability
The next wave of therapies must be: Durable, not transient Tolerable, not trade-off driven Integrated, addressing cardiovascular, renal, and metabolic risk together
Glutaryl is our flag ship product and 95% of people just need the Glutaryl
A balanced diet, regular sleep, exercise, and avoiding smoking can help support healthy glutathione levels